Gendicine: Difference between revisions
Content deleted Content added
Velayinosu (talk | contribs) →History: cleanup ref |
consistent citation formatting |
||
| (13 intermediate revisions by 8 users not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|Gene therapy medication}} |
|||
{{Use dmy dates|date=June 2023}} |
|||
{{Primary sources|date=June 2018}} |
{{Primary sources|date=June 2018}} |
||
{{Infobox drug |
|||
| drug_name = |
|||
| INN = |
|||
| type = <!-- empty --> |
|||
| image = |
|||
| width = |
|||
| alt = |
|||
| caption = |
|||
<!-- Gene therapy data --> |
|||
'''Gendicine''' is a recombinant [[adenovirus]] engineered to express [[wildtype]]-[[p53]] (rAd-p53). This virus is designed to treat patients with tumors which have mutated p53 genes. |
|||
| gt_target_gene = |
|||
| gt_vector = |
|||
| gt_nucleic_acid_type = |
|||
| gt_editing_method = |
|||
| gt_delivery_method = |
|||
<!-- Clinical data --> |
|||
== History == |
|||
| pronounce = |
|||
Gendicine is the first [[gene therapy]] product approved for clinical use in humans. Gendicine is manufactured by [[Shenzhen SiBiono GeneTech]]. Gendicine was approved in 2003 by the Chinese [[SFDA|State Food and Drug Administration]] to treat head and neck [[squamous cell carcinoma]].<ref name=Gend>{{cite journal|vauthors=Pearson S, Jia H, Kandachi K|title=China approves first gene therapy|journal=Nature Biotechnology|year=2004|volume=22|issue=1|pages=3–4|pmid=14704685|doi=10.1038/nbt0104-3|pmc=7097065}}</ref> |
|||
| tradename = |
|||
| Drugs.com = |
|||
| MedlinePlus = |
|||
| licence_CA = <!-- Health Canada may use generic or brand name (generic name preferred) --> |
|||
| licence_EU = <!-- EMA uses INN (or special INN_EMA) --> |
|||
| DailyMedID = <!-- DailyMed may use generic or brand name (generic name preferred) --> |
|||
| licence_US = <!-- FDA may use generic or brand name (generic name preferred) --> |
|||
| pregnancy_ |
|||
| pregnancy_ |
|||
| pregnancy_category = |
|||
| dependency_liability = |
|||
| addiction_liability = |
|||
| routes_of_administration = |
|||
| class = |
|||
| ATCvet = |
|||
| ATC_prefix = None |
|||
| ATC_suffix = |
|||
| ATC_supplemental = |
|||
| biosimilars = |
|||
<!-- Legal status --> |
|||
Contusugene ladenovec (Advexin), a similar gene therapy developed by [[Introgen]] that also uses adenovirus to deliver the p53 gene, was turned down by the FDA in 2008<ref>{{cite journal|author=Osborne R|year=2008|title=Ark floats gene therapy's boat, for now|journal=Nature Biotechnology|volume=26|pages=1057–1059|doi=10.1038/nbt1008-1057|pmid=18846056|number=26}}</ref> and withdrawn by the maker from the EMA approval shortly after.<ref>{{cite web|url=https://www.ema.europa.eu/en/medicines/human/withdrawn-applications/advexin |title=Advexin: Withdrawal of the marketing authorisation application| author=[[European Medicines Agency]]|accessdate=9 August 2020}}</ref> |
|||
| legal_ |
|||
| legal_ |
|||
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F --> |
|||
| legal_BR_comment = |
|||
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> |
|||
| legal_CA_comment = |
|||
| legal_DE = <!-- Anlage I, II, III or Unscheduled --> |
|||
| legal_DE_comment = |
|||
| legal_NZ = <!-- Class A, B, C --> |
|||
| legal_NZ_comment = |
|||
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C --> |
|||
| legal_UK_comment = |
|||
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|||
| legal_US_comment = |
|||
| legal_EU = |
|||
| legal_EU_comment = |
|||
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV --> |
|||
| legal_UN_comment = |
|||
| legal_status = Rx-only |
|||
<!-- Pharmacokinetic data --> |
|||
| bioavailability = |
|||
| protein_bound = |
|||
| metabolism = |
|||
| metabolites = |
|||
| onset = |
|||
| elimination_half-life = |
|||
| duration_of_action = |
|||
| excretion = |
|||
<!-- Identifiers --> |
|||
| CAS_number = |
|||
| CAS_supplemental = |
|||
| PubChem = |
|||
| IUPHAR_ligand = |
|||
| DrugBank = |
|||
| ChemSpiderID = |
|||
| UNII = |
|||
| KEGG = |
|||
| ChEBI = |
|||
| ChEMBL = |
|||
| NIAID_ChemDB = |
|||
| PDB_ligand = |
|||
| synonyms = |
|||
<!-- Chemical and physical data --> |
|||
| IUPAC_name = |
|||
| chemical_formula_ref = |
|||
| chemical_formula = |
|||
| C= | H= | Ag= | Al= | As= | Au= | B= | Bi= | Br= | Ca= | Cl= | Co= | F= | Fe= | Gd= | I= |
|||
| K= | Li= | Mg= | Mn= | N= | Na= | O= | P= | Pt= | S= | Sb= | Se= | Sr= | Tc= | Zn= | charge= |
|||
| molecular_weight = |
|||
| molecular_weight_comment = |
|||
| SMILES = |
|||
| StdInChI = |
|||
| StdInChI_comment = |
|||
| StdInChIKey = |
|||
| density = |
|||
| density_notes = |
|||
| melting_point = |
|||
| melting_high = |
|||
| melting_notes = |
|||
| boiling_point = |
|||
| boiling_notes = |
|||
| solubility = |
|||
| sol_units = |
|||
| specific_rotation = |
|||
}} |
|||
'''Gendicine''' is a [[gene therapy]] medication used to treat patients with head and neck [[squamous cell carcinoma]] linked to [[Mutation|mutations]] in the [[TP53 gene|''TP53'' gene]]. It consists of recombinant [[adenovirus]] engineered to code for [[p53 protein]] (rAd-p53) and is manufactured by [[Shenzhen SiBiono GeneTech]]. |
|||
Gendicine was the first gene therapy product to obtain regulatory approval for clinical use in humans<ref>{{cite journal | vauthors = Zhang WW, Li L, Li D, Liu J, Li X, Li W, Xu X, Zhang MJ, Chandler LA, Lin H, Hu A, Xu W, Lam DM | display-authors = 6 | title = The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic | journal = Human Gene Therapy | volume = 29 | issue = 2 | pages = 160–179 | date = February 2018 | pmid = 29338444 | doi = 10.1089/hum.2017.218 | doi-access = free }}</ref> after Chinese [[SFDA|State Food and Drug Administration]] approved it in 2003.<ref name="Gend">{{cite journal | vauthors = Pearson S, Jia H, Kandachi K | title = China approves first gene therapy | journal = Nature Biotechnology | volume = 22 | issue = 1 | pages = 3–4 | date = January 2004 | pmid = 14704685 | pmc = 7097065 | doi = 10.1038/nbt0104-3 }}</ref> |
|||
__TOC__ |
|||
==Mechanism of action== |
==Mechanism of action== |
||
Gendicine enters the tumour cells by way of receptor-mediated endocytosis and begins to over-express genes coding for the p53 protein needed to fight the tumour.<ref>{{Cite |
Gendicine enters the tumour cells by way of receptor-mediated endocytosis and begins to over-express genes coding for the p53 protein needed to fight the tumour.<ref>{{Cite journal|url = http://www.biopharminternational.com/genesis-gendicine-story-behind-first-gene-therapy|title = The Genesis of Gendicine: The Story Behind the First Gene Therapy|date = May 1, 2004|journal = Biopharm International| vauthors = Peng Z | series=BioPharm International-05-01-2004 | volume=17 | issue=5 }}</ref> Ad-p53 seems to act by stimulating the apoptotic pathway in tumour cells, which increases the expression of tumour suppressor genes and immune response factors (such as the ability of [[natural killer cell|natural killer (NK) cells]] to exert "bystander" effects). It also decreases the expression of [[multi-drug resistance]], [[vascular endothelial growth factor]] and matrix metalloproteinase-2 genes and blocking transcriptional survival signals. |
||
p53 mutation status of the tumour cells and response to Ad-p53 treatment are not closely correlated.<ref>{{cite journal| |
p53 mutation status of the tumour cells and response to Ad-p53 treatment are not closely correlated.<ref>{{cite journal | vauthors = Peng Z | title = Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers | journal = Human Gene Therapy | volume = 16 | issue = 9 | pages = 1016–1027 | date = September 2005 | pmid = 16149900 | doi = 10.1089/hum.2005.16.1016 }}</ref> Ad-p53 appears to act synergistically with conventional treatments such as [[chemotherapy|chemo-]] and [[radiotherapy]]. This synergy still exists in patients with chemotherapy and radiotherapy-resistant tumors. Gendicine produces fewer side effects than conventional therapy. |
||
== Related development == |
|||
==References== |
|||
Contusugene ladenovec (Advexin), a similar gene therapy developed by [[Introgene]] that also uses adenovirus to deliver the p53 gene, was turned down by the FDA in 2008<ref>{{cite journal | vauthors = Osborne R | title = Ark floats gene therapy's boat, for now | journal = Nature Biotechnology | volume = 26 | issue = 10 | pages = 1057–1059 | date = October 2008 | pmid = 18846056 | doi = 10.1038/nbt1008-1057 | s2cid = 74421879 }}</ref> and withdrawn by the maker from the EMA approval shortly after.<ref>{{cite web | work = [[European Medicines Agency]] |title=Advexin: Withdrawal of the marketing authorisation application |url=https://www.ema.europa.eu/en/medicines/human/withdrawn-applications/advexin | date = 11 February 2009 |access-date=9 August 2020}}</ref> |
|||
== References == |
|||
{{Reflist}} |
{{Reflist}} |
||
[[Category:Gene delivery]] |
[[Category:Gene delivery]] |
||
[[Category:Adenoviridae]] |
[[Category:Adenoviridae]] |
||
{{Genetics-stub}} |
|||
[[Category:Immunotherapy]] |
[[Category:Immunotherapy]] |
||
[[Category:Gene therapy]] |
[[Category:Gene therapy]] |
||
{{Genetics-stub}} |
|||
Latest revision as of 08:36, 9 November 2023
 |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
Gendicine is a gene therapy medication used to treat patients with head and neck squamous cell carcinoma linked to mutations in the TP53 gene. It consists of recombinant adenovirus engineered to code for p53 protein (rAd-p53) and is manufactured by Shenzhen SiBiono GeneTech.
Gendicine was the first gene therapy product to obtain regulatory approval for clinical use in humans[1] after Chinese State Food and Drug Administration approved it in 2003.[2]
Mechanism of action[edit]
Gendicine enters the tumour cells by way of receptor-mediated endocytosis and begins to over-express genes coding for the p53 protein needed to fight the tumour.[3] Ad-p53 seems to act by stimulating the apoptotic pathway in tumour cells, which increases the expression of tumour suppressor genes and immune response factors (such as the ability of natural killer (NK) cells to exert "bystander" effects). It also decreases the expression of multi-drug resistance, vascular endothelial growth factor and matrix metalloproteinase-2 genes and blocking transcriptional survival signals.
p53 mutation status of the tumour cells and response to Ad-p53 treatment are not closely correlated.[4] Ad-p53 appears to act synergistically with conventional treatments such as chemo- and radiotherapy. This synergy still exists in patients with chemotherapy and radiotherapy-resistant tumors. Gendicine produces fewer side effects than conventional therapy.
Related development[edit]
Contusugene ladenovec (Advexin), a similar gene therapy developed by Introgene that also uses adenovirus to deliver the p53 gene, was turned down by the FDA in 2008[5] and withdrawn by the maker from the EMA approval shortly after.[6]
References[edit]
- ^ Zhang WW, Li L, Li D, Liu J, Li X, Li W, et al. (February 2018). "The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic". Human Gene Therapy. 29 (2): 160–179. doi:10.1089/hum.2017.218. PMID 29338444.
- ^ Pearson S, Jia H, Kandachi K (January 2004). "China approves first gene therapy". Nature Biotechnology. 22 (1): 3–4. doi:10.1038/nbt0104-3. PMC 7097065. PMID 14704685.
- ^ Peng Z (1 May 2004). "The Genesis of Gendicine: The Story Behind the First Gene Therapy". Biopharm International. BioPharm International-05-01-2004. 17 (5).
- ^ Peng Z (September 2005). "Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers". Human Gene Therapy. 16 (9): 1016–1027. doi:10.1089/hum.2005.16.1016. PMID 16149900.
- ^ Osborne R (October 2008). "Ark floats gene therapy's boat, for now". Nature Biotechnology. 26 (10): 1057–1059. doi:10.1038/nbt1008-1057. PMID 18846056. S2CID 74421879.
- ^ "Advexin: Withdrawal of the marketing authorisation application". European Medicines Agency. 11 February 2009. Retrieved 9 August 2020.
 | This genetics article is a stub. You can help Wikipedia by expanding it. |